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The Proto-Oncogene Cot Kinase Participates in
CD3/CD28 Induction of NF-kB Acting through the
NF-kB-Inducing Kinase and IkB Kinases
complex into the nucleus, where it engages cognate kB
enhancer elements and modulates the transcription of
various NF-kB-responsive target genes (Thanos and
Maniatis, 1995; Verma et al., 1995).
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CD3 complex alone is not sufficient to activate optimalUniversity of California San Francisco
cytokine production and cell proliferation (Weiss andSan Francisco, California 94141
Littman, 1994). Additional costimulatory signals pro-
vided by the antigen-presenting cells (APC) are required
(Schwartz, 1992). These signals are generated through
Summary interactions between cell-surface protein ligands, such
as B7-1 (CD80) and B7-2 (CD86), on the APCs and the
The proto-oncogene Cot/Tpl-2 encodes a MAP3K- corresponding CD28 receptors on the T cells (Crabtree
related serine-threonine kinase. Expression of wild and Clipstone, 1994; Chambers and Allison, 1997). The
type Cot activates the IkB kinases (IKK) leading to complete activation of T cells produced by the binding
induction of NF-kB. Conversely, expression of kinase- of ligand to the TCR/CD3 and CD28 receptors induces
deficient Cot inhibits CD3/CD28 but not TNFa induc- expression of interleukin-2 (IL-2) and subsequent cell
tion of NF-kB. These findings suggest the selective division (Linsley and Ledbetter, 1993; Rudd, 1996). IL-2
involvement of Cot/Tpl-2 or a closely related kinase gene expression is controlled in part by its 59 flanking
in the CD3/CD28 costimulatory pathway leading to sequences, which contain critical regulatory regions
induced nuclear expression of NF-kB. In contrast, a corresponding to binding sites for various transcription
kinase-deficient mutant of the NF-kB-inducing kinase factors. These factors include NF-AT, NF-kB, AP-1,
Oct-1, and factors interacting with the CD28 response(NIK) inhibits both CD3/CD28 and TNFa signaling, indi-
element (CD28RE) (Crabtree and Clipstone, 1994; Jaincating that these pathways converge at or prior to
et al., 1995). The CD28RE binds to several members ofthe action of NIK. Consistent with such a sequential
the NF-kB family and NF-ATp (Ghosh et al., 1993; Laifunction of these two kinases, Cot physically assem-
et al., 1995; Rooney et al., 1995; Maggirwar et al., 1997;bles with and phosphorylates NIK in vivo.
McGuire and Iacobelli, 1997; Shapiro et al., 1997) and
is essential for integrating the CD28 costimulatory signal
(Kontgen et al., 1995; Boothby et al., 1997; Doi et al.,Introduction
1997). Stimulation of T cells with antibodies specific for
the TCR or CD3 complexes efficiently activates NF-ATThe NF-kB/Rel family of eukaryotic transcription factors
and stimulates the mitogen-activated protein kinaseplays an essential role in the regulation of inflammatory,
(MAPK) ERK (Weiss and Littman, 1994). In contrast, in-antiapoptotic, and immune responses (Baeuerle and
duction of NF-kB and the Jun N-terminal kinase (JNK)Baltimore, 1996; Baldwin, 1996). NF-kB family members
requires a second costimulatory signal derived from en-are regulated through interactions with a series of cyto-
gagement of the CD28 receptor (Su et al., 1994; Lai etplasmic inhibitory proteins termed IkBs. IkBa is the ma-
al., 1995). NF-kB regulates not only the kB enhancerjor IkB species bound to the prototypic NF-kB (p50/p65)
element of the IL-2 promoter (located at positions 2206transcription factor complex in vivo. Stimulation of cells
to 2195) (Hoyos et al., 1989) but also the CD28RE (posi-with proinflammatory cytokines, such as tumor necrosis
tions 2160 to 2152) (Fraser et al., 1991). The signalingfactor a (TNFa) and interleukin-1b (IL-1b), initiates signal
intermediates involved in activation of NF-kB by CD3/transduction cascades leading to nuclear NF-kB activa-
CD28 costimulation remain undefined.
tion. These signals appear to converge on the NF-kB-
The human proto-oncogene Cot encodes a 467-amino
inducing kinase (NIK) (Malinin et al., 1997), which in turn acid protein that has transforming potential (Miyoshi et
activates the recently identified a and b forms of the al., 1991). At the amino acid level, Cot is 90% identical
IkB kinases (IKK) (DiDonato et al., 1997; Mercurio et al., to the product of the rat Tpl-2 gene, which is involved
1997; Regnier et al., 1997; Woronicz et al., 1997; Zandi et in the progression of T cell lymphomas initiated by Molo-
al., 1997). These IKKs phosphorylate the two regulatory ney murine leukemia virus (MoMuLV) infection (Patriotis
serines located in the N termini of IkB molecules (Brock- et al., 1993). Cot/Tpl-2 is a serine/threonine kinase that
man et al., 1995; Brown et al., 1995; Traenckner et al., is homologous to members of the mitogen-activated
1995; Whiteside et al., 1995; Sun et al., 1996), triggering protein kinase kinase kinase (MAP3K) family. Expression
rapid ubiquitination and proteolysis of IkB in the 26S of the Cot/Tpl-2 oncogene activates intracellular signal-
proteasome complex (Chen et al., 1995; Scherer et al., ing pathways leading to both ERK and JNK activation
1995). The degradation of IkBa unmasks the nuclear (Patriotis et al., 1994; Salmeron et al., 1996). The onco-
localization signal of RelA in the p50/RelA heterodimeric genic properties of the Cot/Tpl-2 oncogene appear to
NF-kB complex, allowing the rapid translocation of this relate to enhanced kinase activity associated with loss
of the C-terminal autoinhibitory domain produced by
MoMuLV insertion (Makris et al., 1993; Ceci et al., 1997).³ To whom correspondence should be addressed (e-mail: wgreene@
Little is known about the physiological function of Cot/gladstone.ucsf.edu).
§ These authors contributed equally to this work. Tpl-2; however, ectopic expression of Cot/Tpl-2 induces
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Figure 1. Cot Mimics the Activating Effects
of Anti-CD3/Anti-CD28 on the CD28RE/AP-1
(RE/AP) Composite Element of the IL-2 Pro-
moter in Jurkat T Cells
Jurkat T cells were transfected with 10 mg
of a luciferase reporter plasmid containing a
composite enhancer motif from the human
IL-2 gene corresponding to the CD28RE and
AP-1 sites (RE/AP-Luc). These cells were also
transfected with 0.5 mg of b-galactosidase
reporter plasmids or plasmids containing mu-
tations in the CD28RE site, the AP-1 site, or
in both sites. After 18 hr, the cultures were
stimulated for 10 hr with antibodies specific
for CD3 (OKT3) (2 mg/ml) or CD28 (2 mg/ml)
alone or in combination as indicated in (A)
and (B). (C) Jurkat T cells were transfected
with the wild-type and mutant RE/AP reporter
plasmids and a plasmid expressing Cot. Cell
lysates were prepared 24 hr after transfec-
tion. (D) Jurkat T cells were transfected with
RE/AP reporter plasmid and graded doses of
the kinase-deficient K167M mutant of Cot. After 18 hr, the cultures were stimulated with or without antibodies specific for CD3 (OKT3) (2 mg/
ml) and CD28 (2 mg/ml) for 8 hr. The lysates were then assayed for luciferase activity. b-galactosidase activity in these lysates was also
measured and used to normalize for differences in transfection efficiency in the various cultures.
transcription of the IL-2 gene in T cells (Ballester et al., pathway initiated following anti-CD3/anti-CD28 costim-
ulation of T cells. To test this hypothesis, we first exam-1997; Tsatsanis et al., 1998). Moreover, stimulation of
T cells with anti-CD3 antibodies coupled with ectopic ined whether ectopic expression of Cot is able to acti-
vate a luciferase reporter plasmid (RE/AP-luciferase)expression of Cot significantly enhances IL-2 production
(Ballester et al., 1997), raising the possibility that Cot containing the CD28RE and the flanking AP-1 site (RE/
AP) from the IL-2 promoter (Shapiro et al., 1997). Wemay be involved in the CD3/CD28 costimulatory signal-
ing pathway. selected this subregion of the IL-2 promoter because it
is essential for the integration of the costimulatory CD3In the current studies, we have examined the role of
Cot/Tpl-2 in T cell activation. Our findings demonstrate and CD28 signals. Specifically, Jurkat T cells must be
stimulated with both anti-CD3 and anti-CD28 antibodiesthat ectopic expression of Cot mimics CD3/CD28 co-
stimulation leading to activation of an enhancer element to activate RE/AP-dependent transcription (Shapiro et
al., 1997) (Figure 1A). Ectopic expression of Cot mim-composed of the CD28RE and the NF-IL-2B AP-1 sites
(RE/AP) from the IL-2 gene. Further, we show that the icked anti-CD3/anti-CD28 costimulation, potently acti-
vating RE/AP-dependent transcription (Figures 1B andinduction of RE/AP activity by Cot is dependent on NF-
kB and requires activation of both IKKa and IKKb. Con- 1C). Both Cot and anti-CD3/anti-CD28 costimulation
were dependent on the presence of the CD28RE andsistent with these findings, ectopic expression of Cot
induces both IKK enzymatic activity and nuclear NF-kB the AP-1 sites, since reporters containing mutations in
either site failed to respond to Cot or the anti-CD3 andexpression. Expression of a kinase-deficient mutant of
Cot selectively impairs CD3/CD28 induction of NF-kB anti-CD28 antibodies (Figures 1B and 1C). These find-
ings suggest that Cot activates transcription factors thatbut does not interfere with TNFa-activation of NF-kB.
In contrast, kinase-deficient NIK blocks both the CD3/ effectively induce both the CD28RE and AP-1 sites. To
further examine the role of Cot in CD3/CD28 signaling,CD28 and TNFa pathways as well as Cot activation of
the IKKs. Together, these data suggest that Cot partici- a kinase-deficient mutant of Cot, K167M, was examined
for its ability to inhibit CD3/CD28-induced RE/AP activa-pates in the CD3/CD28 costimulatory pathway and that
Cot is positioned upstream of a second MAP3K, NIK, tion. Graded doses of Cot (K167M) potently inhibited
anti-CD3/anti-CD28-induced RE/AP activation (Figurein this signaling cascade leading to NF-kB induction.
1D), suggesting that Cot or a Cot-like kinase plays an
important role in this signaling pathway.
Results
Ectopic Expression of Cot Recapitulates CD3/CD28 Cot-Induced CD28RE/AP-Dependent Transcription
Involves NF-kBCostimulation of the CD28RE/AP-1 Composite
Enhancer in the IL-2 Promoter Ectopically expressed Cot/Tpl-2 activates nuclear ex-
pression of NF-ATp (Tsatsanis et al., 1998). Since NF-Ectopic expression of the Cot/Tpl-2 proto-oncogene
product activates IL-2 production in T cells (Ballester et ATp can bind to a DNA probe corresponding to the
CD28RE in vitro (Rooney et al., 1995; Maggirwar et al.,al., 1997; Tsatsanis et al., 1998), and this activation is
significantly enhanced by stimulation with anti-CD3 anti- 1997), we examined the potential role of NF-AT in Cot-
induced RE/AP activation by blocking NF-AT inductionbodies. Based on these findings, we hypothesized that
Cot/Tpl-2 may represent an intermediate in a signaling with cyclosporin A. At a concentration of 100 mM, which
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Figure 2. Cot Activation of RE/AP Involves
NF-kB but Not NF-AT
(A) Jurkat T cells were transfected with 3 mg
of Cot expression plasmids, 10 mg of RE/AP-
Luc reporter, and 0.5 mg of b-galactosidase
reporter in the presence or absence of 0.1
mg of an expression plasmid encoding the
IkBa(SS32/36AA) mutant. After 18 hr, se-
lected cultures were treated with 100 mM
cyclosporin A for 6 hr.
(B) Jurkat T cells were transfected with 3 mg
of Cot expression plasmid, 10 mg of AP-1-
Luc reporter, and 0.5 mg of b-galactosidase
reporter in the presence or absence of 0.1 mg
of the IkBa(SS32/36AA) expression plasmid.
(C and D) Jurkat T cells were transfected with
3 mg of Cot expression plasmid together with
10 mg of the RE/AP-Luc and 0.5 mg of the
b-galactosidase reporter plasmids in the pres-
ence or absence of wild-type or kinase-defi-
cient versions of IKKa (C) and IKKb (D). After
20 hr, cell lysates were prepared from these
cultures, and luciferase activities were deter-
mined.
inhibited ionomycin- and PMA-induced NF-AT-depen- Ectopic Expression of Cot Induces Endogenous
dent luciferase activity (data not shown), cyclosporin A IKKa Enzymatic Activity and NF-kB Activation
exerted no detectable effects on Cot-induced activation We next examined whether ectopic expression of Cot
of RE/AP-dependent transcription (Figure 2A). This re- leads to the activation of the IKKs. Anti-IKKa antibodies
sult suggests that cyclosporin A sensitive NF-AT activa- (H744, Santa Cruz Biotechnology) were used to immuno-
tion is not involved in Cot-induced RE/AP-dependent precipitate endogenous IKKa (and perhaps IKKb) from
transcription. However, these findings do not exclude a cell lysates of 293 cells transfected with a Cot expres-
cyclosporin A resistant pathway of NF-AT induction by sion plasmid. IKKa activity was measured by examining
Cot. the extent of phosphorylation of exogenously added
Since members of the NF-kB/Rel family also bind to GST-IkBa(1±62) in immunocomplex kinase assays. Ex-
the CD28RE (Ghosh et al., 1993), we next examined pression of wild-type Cot activated endogenous IKKa,
whether Cot-induced RE/AP-dependent transcription whereas the kinase-deficient mutant did not (Figure 3A).
involves NF-kB or Rel-related factors. Expression of a We next compared the ability of Cot to activate endog-
dominant-active mutant of IkBa, IkBa(SS32/36AA), which enous IKKa with two other MAP3Ks, NIK and MEKK1,
cannot be phosphorylated or degraded, completely which have been reported to activate IKKs (Regnier et
abolished Cot-induced RE/AP-dependent transcription al., 1997; Lee et al., 1998). Consistent with previous
(Figure 2A). In contrast, expression of this IkBa mutant studies, NIK and MEKK1 activated endogenous IKKa to
did not inhibit but rather enhanced Cot induced AP-1- different extents (Karin and Delhase, 1998) (Figure 3B).
dependent transcription (AP-1-Luciferase, Stratagene The induction of endogenous IKKa enzymatic activity
Inc.), demonstrating the specificity of the observed in- reached maximal levels at low doses of Cot expression
hibitory effects on NF-kB (Figure 2B). These results im- vector (0.15 mg). The level of induction of IKKa enzymatic
plicate the participation of NF-kB/Rel factors in the activity by Cot at 0.15 mg of expression vector was
Cot-induced RE/AP response. It remains uncertain why comparable to that induced by TNFa (Figure 3B, lanes
expression of the IkBa mutant significantly enhanced
3 and 5±7). Interestingly, the induction of IKKa enzymatic
Cot-induced AP-1-luciferase activity. It is possible that
activity by NIK was significantly higher than that pro-
inhibition of the Cot-activated NF-kB pathways is asso-
duced by either TNFa or Cot expression (Figure 3C,ciated with an exaggerated stimulation of the JNK path-
lanes 12±14). Ectopic expression of MEKK1 led to theway (Salmeron et al., 1996).
weakest induction of endogenous IKKa enzymatic ac-Having determined that Cot-induced RE/AP-depen-
tivity.dent transcription involves NF-kB activation at or before
In light of these results, we next examined whetherphosphorylation of IkBa, we next explored whether the
Cot could activate a pure NF-kB-dependent luciferaseIKKs participated in this response. The Cot expression
reporter (NF-kB-Luc, Stratagene Inc.). Ectopic expres-vector was cotransfected with plasmids encoding either
sion of Cot in 293 cells induced luciferase activity fromwild-type or kinase-deficient versions of IKKa (Figure
the kB-dependent reporter plasmid in a dose-depen-2C) or IKKb (Figure 2D) together with the RE/AP reporter
dent manner (Figure 3C). This activation was dependentplasmid. The RE/AP-dependent luciferase activity in-
on Cot kinase activity, since a kinase-deficient mutantduced by Cot was inhibited by kinase-deficient mutants
of Cot failed to induce this reporter construct (Figureof either IKKa or IKKb (Figures 2C and 2D), suggesting
3C). These results demonstrate that ectopic expressionthat the activation of both IKKa and IKKb is involved in
of Cot activates IKKa and stimulates nuclear NF-kB ex-the Cot-induced signaling pathway leading to activation
of the CD28RE/AP element. pression.
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Figure 3. Cot Activates Endogenous IKKa
Activity and Induces NF-kB-Dependent Gene
Expression
(A) 293 cells were plated at 5 3 105 cells/well
in six-well plates and transfected 24 hr later
with 1 mg of plasmid DNA encoding Myc-
tagged wild-type or kinase-deficient Cot.
After 15 hr, in vitro kinase reactions were per-
formed on anti-IKKa immunoprecipitates us-
ing GST-IkBa(1±62) as an exogenously added
substrate. The kinase reactions were ana-
lyzed by SDS-PAGE, transfer to a nitrocellu-
lose membrane, and autoradiography. The
phosphorylated IkBa(1±62) is indicated on
the right. The middle panel shows the levels
of immunoprecipitated endogenous IKKa in
the different transfected cultures. The lower
panel shows the level of expression of wild-
type and kinase-deficient Cot in these cell
lysates.
(B) 293 cells were transfected with 0.05, 0.15,
0.5, or 1.5 mg of plasmid DNA encoding Myc-
tagged Cot or HA-tagged MEKK1 or with
0.05, 0.15, or 0.5 mg of plasmid DNA encoding
Myc-tagged NIK. After 15 hr, in vitro kinase
reactions were performed as described in (A).
Fold induction was quantitated using a phos-
phorimager.
(C) Cot expression plasmid (50, 100, and 200
ng) was transfected into 293 cells together
with 10 ng of kB-luciferase and 100 ng of
b-galactosidase reporter plasmids. Total
DNA concentration was held constant at 2
mg by supplementation with the parental pRK
vector DNA. Cell lysates were prepared from
the cultures 20 hr after transfection, and lucif-
erase activities were determined. The b-galac-
tosidase activities in these lysates were deter-
mined and used to normalize for differences
in transfection efficiency. IP, immunoprecipi-
tation; IB, immunoblot.
A Kinase-Deficient Mutant of Cot Selectively both TNFa-and CD3/CD28 costimulation-induced NF-
kB activation (Figure 4C), suggesting that NIK may playInhibits CD3/CD28-Induced NF-kB Activation
To identify the signaling components involved in CD3/ a role in both TNFa and CD3/CD28 signaling pathways
leading to NF-kB activation. NIK may thus represent aCD28 signaling, kinase-deficient mutants of IKKa(K44M),
IKKb(K44A), Cot(K167M), or NIK(KK429/430AA), were common signaling intermediate in both pathways and as
such likely resides downstream of Cot in the CD3/CD28cotransfected with the NF-kB-luciferase and b-galac-
tosidase reporter plasmids into Jurkat T cells. For each signaling pathway leading to the activation of NF-kB.
sample, half of the transfected cells were stimulated
with TNFa, while the remaining half were stimulated with Cot Physically Assembles with NIK and IKKa In Vivo
To further investigate the possible molecular interplay ofa combination of anti-CD3 and anti-CD28 antibodies.
IKKa(K44M), IKKb(K44A), or combinations of these two Cot, NIK, and IKKa, we examined whether Cot physically
associates with either NIK or IKKa in vivo. 293 cells weremutants potently inhibited both TNFa- and CD3/CD28-
induced NF-kB activation (Figure 4A). Although the kinase- transfected with Myc-tagged Cot and either T7-tagged
IKKa or T7-tagged NIK and then immunoprecipitateddeficient mutant of Cot had no effect on TNFa-induced
NF-kB activation, Cot (K167M) potently inhibited anti- with anti-T7 antibodies. The immunoprecipitates were
subjected to SDS-PAGE and immunoblotted with anti-CD3/anti-CD28-induced NF-kB activation (Figure 4B).
These findings suggest that Cot mediates signaling in Myc antibodies. Myc-Cot coimmunoprecipitated with
T7-IKKa and T7-NIK (Figure 5A, lanes 2 and 3 of topthe CD3/CD28 pathway but not the TNFa pathway lead-
ing to NF-kB activation. We next examined whether NIK panel). In a control experiment, Myc-tagged PAK1 did
not associate with either T7-IKKa or T7-NIK (Figure 5A,is involved in CD3/CD28-induced NF-kB activation. The
kinase-deficient mutant of NIK, KK429/430AA, inhibited lanes 5 and 6 of top panel). To further examine if Cot
Proto-Oncogene Cot Activates NF-kB
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ability of coimmunoprecipitated NIK or Cot to phosphor-
ylate IKKa. NIK effectively phosphorylated the coimmu-
noprecipitated IKKa(K44M) protein in vitro (Figure 5D,
lane 2), whereas Cot, despite assembling with IKKa (Fig-
ure 5D, lower panel), failed to phosphorylate the coim-
munoprecipitating IKKa (Figure 5D, lane 3).
NIK Is a Downstream Target of Cot
Since Cot appeared to have a somewhat stronger affinity
for NIK than IKKa (compare lanes 2 and 3, Figure 5A)
and did not directly phosphorylate IKKa (Figure 5D), we
next examined whether Cot-induced activation of IKKa
is mediated through NIK. T7-IKKa was cotransfected
with NIK in the presence or absence of a kinase-deficient
mutant of Cot, while in a parallel experiment, T7-IKKa
was cotransfected with Cot in the presence or absence
of a kinase-deficient mutant of NIK. Immunocomplex
kinase assays of IKKa were performed with exogenous
GST-IkBa(1±62) serving as substrate. Both wild-type
NIK and Cot strongly activated T7-IKKa (Figure 6A, lanes
3 and 5 of top panel). Expression of the kinase-deficient
mutant of Cot had no effect on NIK-induced IKKa activa-
tion; however, expression of the kinase-deficient mutant
of NIK completely abolished Cot-induced activation of
IKKa (Figure 6A, lane 6 of top panel). This inhibition was
not apparently due to the NIK protein competing for Cot
binding sites on IKKa, since significant amounts of Cot
coimmunoprecipitated with IKKa despite the presence
of NIK (Figure 6A, compare lanes 5 and 6 of lower panel).
These findings strongly suggest that NIK lies down-
stream of Cot in a signaling pathway leading to NF-kB
activation. To further test this hypothesis, we examined
whether Cot activates phosphorylation of NIK in vivo.
Phosphorylation of a kinase-deficient mutant of NIK was
compared by radiolabeling with [32P]-orthophosphoric
acid in the presence of either wild-type or kinase-defi-
Figure 4. Kinase-Deficient Cot Selectively Inhibits CD3/CD28 but cient versions of Cot (Figure 6B, lanes 2 and 3 of top
Not TNFa Induction of NF-kB
panel). These results revealed significant phosphoryla-
Jurkat T cells were transfected with kinase-deficient mutants of (A)
tion of NIK in the presence of Cot, indicating that CotIKKa(K44M), IKKb(K44A), or a combination of these two plasmids;
functions as an upstream kinase of NIK, inducing either(B) Cot (K167M); (C) NIK (KK429/430AA), together with 10 mg of kB-
directly or indirectly phosphorylation of NIK in vivo.luciferase and 0.5 mg of b-galactosidase reporter plasmids. After
20 hr, the cultures were stimulated with TNFa (20 ng/ml) or anti-
CD3 (2 mg/ml) and anti-CD28 (2 mg/ml) antibodies for 8 hr. Cell Discussion
lysates were then prepared from the cultures, and luciferase activi-
ties were determined. The b-galactosidase activities of these lysates
The Cot/Tpl-2 proto-oncogene corresponds to a serine/were measured and used to normalize for differences in transfection
threonine kinase that is a member of the MAP3K familyefficiency. All data are presented as percentage induction of lucifer-
of proteins. Cot/Tpl-2 stimulates both the ERK and JNKase activity obtained with the inducer alone. The standard deviations
were derived from independent triplicate transfections. pathways, which likely contribute to its ability to activate
T-lymphocytes and to induce IL-2 production (Patriotis
et al., 1994; Salmeron et al., 1996). In the case of physio-associates with NIK and the IKKs in nonoverexpressed
logical activation of the IL-2 gene, stimulation throughT cells, expression plasmids encoding Myc-Cot and T7-
the TCR/CD3 complex alone is insufficient. Rather, aNIK were transfected into Jurkat T cells. Immunoprecipi-
second costimulatory signal provided by ligand engage-tation with anti-Myc antibodies coprecipitated the T7-
ment of cell-surface receptor molecules such as CD28NIK proteins (Figure 5B). In addition, Myc-Cot stably
is required (Schwartz, 1992). Ectopic expression of theexpressed in Jurkat T cells was shown to physically bind
Cot/Tpl-2 proto-oncogene is sufficient to induce IL-2to endogenous IKKa (Figure 5C). Together, these results
gene expression in human Jurkat and murine EL-4 Tsuggest that Cot, NIK, and IKKa may form a higher-
cells, and this response is significantly enhanced byorder complex in T cells. To determine whether Cot, like
further stimulation with anti-CD3 antibodies or iono-NIK, can phosphorylate IKKa in vitro (Ling et al., 1998),
mycin and phorbol ester (Ballester et al., 1997; Tsatsanisexpression vectors encoding kinase-deficient (K44M)
et al., 1998). These findings suggest that ectopic expres-IKKa and wild-type NIK or Cot were cotransfected into
sion of Cot/Tpl-2 may mimic the CD3/CD28 costimula-293 cells. IKKa was then immunoprecipitated and sub-
jected to an immunocomplex kinase reaction to test the tory signal. In the current study, we demonstrate that
Immunity
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Figure 5. Cot Physically Assembles with NIK
and IKKa In Vivo
(A) 293 cells were seeded at 5 3 105/well in
six-well plates and transfected 24 hr later with
2 mg of Myc-tagged Cot or Myc-tagged PAK1
expression vectors in the presence or ab-
sence of 2 mg of T7-tagged IKKa or T7-tagged
NIK expression vectors. After 20 hr, cell ly-
sates were prepared. Aliquots of the cell ly-
sates were immunoprecipitated with anti-T7
antibodies covalently conjugated to beads.
These immunoprecipitates were then sub-
jected to SDS-PAGE and immunoblotted with
anti-Myc (top panel) or anti-T7 antibodies
(middle panel). Aliquots of the cell lysates
were subjected to SDS-PAGE and immu-
noblotted with anti-Myc antibodies to assess
the expression levels of the individual pro-
teins (bottom panel).
(B) Jurkat T cells were transfected with 40 mg
of Myc-Cot and 40 mg of T7-NIK. Cell lysates
were prepared after 24 hr. Half of the lysates
were immunoprecipitated with nonspecific
serum and the other half with anti-Myc anti-
bodies. The immunoprecipitates were sub-
jected to SDS-PAGE and immunoblotted with
anti-T7 (upper panel) or anti-Myc antibodies
(lower panel).
(C) Lysates from Jurkat T cells stably expressing Myc-Cot were immunoprecipitated with anti-IKKa antibodies. The immunoprecipitates were
immunoblotted with anti-Myc (upper panel) or anti-IKKa antibodies (lower panel).
(D) 293 cells were transfected with 2 mg of T7-tagged IKKa(K44M) expression vectors and 2 mg of Myc-tagged NIK or Myc-tagged Cot
expression vectors. After 20 hr, in vitro kinase reactions were performed on anti-T7 immunoprecipitates from these cell lysates. The resulting
kinase reactions were subjected to SDS-PAGE, transferred to nitrocellulose membranes, and analyzed by autoradiography. The phosphorylated
IKKa(K44M) is indicated on the right in the upper panel. The middle panel shows the levels of immunoprecipitated IKKa and the bottom panel
shows levels of coimmunoprecipitated NIK and Cot proteins.
Cot, like CD3/CD28 costimulation, activates transcrip- expression of a dominant-active, phosphorylation resis-
tant mutant of IkBa, IkBa (SS32/36AA), as well as ex-tion from a composite enhancer element composed of
the CD28RE and the flanking NF-IL-2B AP-1 site (RE/ pression of kinase-deficient mutants of IKKa and IKKb,
potently inhibits Cot-induced RE/AP activation. Consis-AP) in the IL-2 enhancer. We find that the stimulation
of RE/AP activity by Cot is dependent on the phosphory- tent with this observation, we further demonstrate that
ectopically expressed Cot activates endogenous IKKalation of IkBa leading to the induction of NF-kB, since
Figure 6. NIK Functions As a Downstream
Target of Cot
(A) 293 cells were seeded at 5 3 105/well in
six-well plates and transfected 24 hr later with
1 mg of T7-tagged IKKa expression vectors
and 1 mg of Myc-tagged-NIK or Myc-tagged-
Cot expression vectors in the presence or
absence of Myc-tagged NIK(KK429/430AA)
or Myc-tagged Cot(K167M) as indicated.
After 15 hr, in vitro kinase reactions were per-
formed on anti-T7 immunoprecipitates in the
presence of the exogenous GST-IkBa(1±62)
substrate. The reaction products were ana-
lyzed by SDS-PAGE, transferred to a nitrocel-
lulose membrane, and subjected to autoradi-
ography. The phosphorylated IkBa(1±62) is
indicated on the right in the upper panel. The
middle panels show the amounts of immuno-
precipitated T7-IKKa, Myc-NIK, and Myc-
Cot. The lower panel shows expression levels
of wild-type and kinase-deficient Cot and NIK
in the cell lysates.
(B) 293 cells were transfected with Myc-tagged kinase-deficient NIK in the presence or absence of Myc-tagged wild-type or kinase-deficient
Cot. After 18 hr, these cultures were incubated in phosphate-free medium for 1 hr and radiolabeled for 2 hr with [32P]-orthophosphoric acid,
and NIK and Cot were immunoprecipitated with anti-Myc antibodies. The resulting immunoprecipitates were separated by SDS-PAGE,
transferred to a nitrocellulose membrane, and analyzed by autoradiography. The upper panel shows the levels of phosphorylated NIK. The
lower panel shows the levels of NIK and Cot proteins in the immunoprecipitates.
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Figure 7. Signaling Pathways Leading to Ac-
tivation of IKKa/b
Our working model suggests that the TNFa
and CD3/CD28 costimulatory signaling path-
ways converge on NIK, leading to activation
of the IKK complex. Cot/Tpl-2 is a component
of the CD3/CD28 costimulatory pathway that
directly or indirectly modulates NIK activity.
The data suggest an unexpected interplay
between two MAP3Ks that act sequentially
in the CD3/CD28 signaling pathway leading
to NF-kB induction.
activity and induces NF-kB-dependent reporter gene does not fully activate either the JNK or NF-kB pathway
in Jurkat T cells or induce IL-2 gene expression. Theexpression. Thus, Cot/Tpl-2 joins NIK and MEKK1 as
the third MAP3K that can induce NF-kB through the induction of full JNK and NF-kB activity requires an
additional costimulatory signal provided by ligand en-IKKs.
Earlier studies demonstrated that the transforming gagement of the CD28 receptor (Su et al., 1994; Lai et
al., 1995). Consistent with this observation, CD3/CD28properties of the Cot/Tpl-2 oncogene relates to a dereg-
ulated, heightened level of kinase activity produced by costimulation potently induces the enzymatic activity of
endogenous IKK, whereas stimulation with either anti-truncation of a C-terminal autoinhibitory domain as a
consequence of viral insertion (Ceci et al., 1997). How- CD3 or anti-CD28 alone fails to activate these kinases
(Harhaj and Sun, 1998; Lin et al. unpublished data).ever, the kinase-induced biochemical events that lead
to the emergence of T cell lymphomas remain unknown. Evidence showing that anti-CD3/anti-CD28 costimu-
lation induces endogenous Cot enzymatic activity wouldThe NF-kB family of transcription factors plays a critical
role in controlling cellular growth and survival (Beg et clearly implicate this kinase as a signaling intermediate
in this pathway. However, such experiments are notal., 1995; Beg and Baltimore, 1996; Liu et al., 1996; Van
et al., 1996; Wang et al., 1996). Accordingly, components currently possible because an antibody that immuno-
precipitates detectable levels of enzymatically activeof the intracellular signaling pathways leading to NF-kB
activation may be the products of proto-oncogenes. endogenous Cot protein is not available. To circumvent
this technical problem, we derived Jurkat T cells stablyConstitutive expression of nuclear NF-kB is associated
with the transformation of various cells. For example, it expressing an epitope-tagged version of Cot. Unfortu-
nately, this ectopically expressed Cot displayed consti-has been suggested that NF-kB plays an important role
in cellular transformation mediated by the BCR-Abl on- tutive kinase activity even in the absence of CD3/CD28
costimulation. However, we have found that a kinase-cogene product (Reuther et al., 1998) and the HTLV-I
Tax oncoprotein (Yamaoka et al., 1996). Cellular trans- deficient mutant of Cot selectively and effectively inhib-
its CD3/CD28-induced but not TNFa-induced, NF-kBformation associated with NF-kB activation may be due
in part to the antiapoptotic properties of NF-kB (Beg et activation in Jurkat T cells (Figure 4B). This result cou-
pled with Cot activation of RE/AP activity strongly sug-al., 1995; Beg and Baltimore, 1996; Liu et al., 1996; Van
et al., 1996; Wang et al., 1996). Our finding that Cot gests that Cot/Tpl-2 participates in the CD3/CD28
costimulatory signaling pathway leading to NF-kB acti-activates NF-kB provides a potential molecular mecha-
nism contributing to the oncogenic property of Cot/ vation. However, because of potential cross inhibition
of different signaling pathways by dominant-negativeTpl-2. Activation of NF-kB by Cot may not only block
apoptosis but also may stimulate cell proliferation through kinase mutants, we cannot rule out the possibility that
a kinase homologous to Cot may be involved in CD3/the production of T cell growth factors such as IL-2.
Future studies will address the role of NF-kB in Cot/Tpl- CD28 signaling.
Our results showing that a kinase-deficient mutant of2-mediated transformation and the potential participa-
tion of various cytokines in tumorigenesis. NIK inhibited both TNFa and CD3/CD28 costimulation
signaling pathways leading to NF-kB activation raisedLittle is known about receptor systems that utilize Cot
as an intracellular signaling intermediate. When ectopi- the possibility that these two signaling pathways may
converge at the level of NIK. Our current working modelcally expressed in T cells, Cot/Tpl-2 induces transcrip-
tion of the IL-2 gene (Ballester et al., 1997; Tsatsanis et is presented in Figure 7. Consistent with this model, Cot
physically assembles with NIK and IKKa when theseal., 1998), suggesting that Cot/Tpl-2 may represent a
component in the physiological signaling pathway lead- proteins are ectopically expressed. Further, although
bound to IKKa, Cot does not phosphorylate this kinaseing to IL-2 production. Moreover, stimulation of T cells
ectopically expressing Cot with anti-CD3 antibodies sig- directly in vitro (Figure 5D). Cot binds much more avidly
to NIK than to IKKa and induces NIK phosphorylationnificantly enhances IL-2 production, raising the possibil-
ity that Cot may be involved in the CD3/CD28 costimula- in vivo (Figure 6B). The notion that Cot activates NIK is
further supported by the finding that a kinase-deficienttory pathway. Engagement of the TCR/CD3 complex
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room temperature. Cells from this cell suspension (0.4 ml) were usedmutant of NIK blocks Cot-induced activation of IKKa,
for electroporation pulsing at 250 V, 950 mF in 0.4-cm cuvetteswhile a kinase-deficient mutant of Cot exerts no effect
with a BioRad Gene Pulser. Cells were then incubated at roomon NIK-induced activation of IKKa. These data suggest
temperature for 10 min and resuspended in 8 ml of complete RPMI
that Cot functions upstream of NIK in the CD3/CD28- medium. After 15±20 hr, selected cultures were stimulated with TNFa
costimulation signaling pathway leading to activation (20 ng/ml), anti-human CD3 monoclonal antibodies (OKT3) alone,
and anti-human CD28 monoclonal antibodies alone or in combina-of NF-kB (Figure 7). It is possible that Cot/Tpl-2 is a
tion as indicated. Luciferase activity was typically measured 15±25downstream target of the PI3 kinase/Akt signaling path-
hr after transfection with the enhanced luciferase assay kit andway that has been implicated in CD28 signaling; this
a Microbeta 1450 Trilux Luminesence Counter (Wallac Company,possibility is currently under investigation.
Turku, Finland). All transfections included the 6RZ plasmid to nor-
Both Cot/Tpl-2 and NIK are members of the MAP3K malize for differences in gene transfer efficiency by assay of b-galac-
family of kinases. The typical MAP kinase cascade that tosidase activity.
responds to extracellular signals involves the sequential
Immunoprecipitation and Immunoblottingaction of MAP3K-MAP2K-MAPK. Our finding that two
293 cells (5 3 105 cells/well) were transfected in six-well plates byMAP3Ks (Cot/Tpl-2 and NIK) are sequential intermedi-
calcium phosphate precipitation of DNA and lysed 24 hr later in ELBates in a signaling pathway is unexpected. These find-
buffer containing 1.5% (v/v) NP-40, 250 mM NaCl, 50 mM Hepes
ings raise the possibility that different MAP3Ks may be (pH 7.4), 1 mM EDTA, and the following protease inhibitors: 1 mM
able to form heteromolecular complexes mediating in- PMSF, 5 mg/ml antipain, 5 mg/ml aprotinin, 5 mg/ml leupeptin, 0.5
tracellular signals. Although both NIK and Cot/Tpl-2 are mg/ml pepstatin, 7.5 mg/ml bestatin, 4 mg/ml phosphoroamidon, and
5 mg/ml trypsin inhibitor. Lysates were immunoprecipitated withMAP3Ks, NIK appears to activate a specific downstream
anti-T7-Tag antibody linked to agarose beads (Novagen, Madison,component (IKK) leading to NF-kB activation, whereas
WI). Immunoprecipitates were washed three times in ELB buffer,Cot/Tpl-2 activates several signaling pathways, includ-
subjected to SDS-PAGE, transferred to nitrocellulose membranes,
ing ERK, JNK, NF-AT (Patriotis et al., 1994; Salmeron et and immunoblotted with anti-Myc-Tag antibodies. For coimmuno-
al., 1996; Tsatsanis et al., 1998), and NF-kB. The re- precipitation of Myc-Cot and T7-NIK in Jurkat T cells, 10 mg of each
stricted activity of NIK could be due to its direct binding expression plasmid were transfected into Jurkat T cells as described
above. Four transfected samples were pooled together for immuno-to IKKa and other components in the IKK complex. In
precipitation. For coimmunoprecipitation of Myc-Cot and endoge-contrast, Cot/Tpl-2 may interact with various adaptor
nous IKKa, IKKa was immunoprecipitated with anti-IKKa (H744,molecules that participate in these different signaling
Santa Cruz Biotech) antibodies from 1 3 107 Jurkat T cells stably
pathways leading to its pleiotropic activities. In future expressing Myc-Cot. The presence of Myc-Cot in the immunopre-
studies, we will seek to determine if different domains cipitates was revealed by immunoblotting with anti-Myc antibodies.
of Cot/Tpl-2 are responsible for these pleiotropic signals
Immune Complex Kinase Assaysand to identify the specific adaptor molecules that bind
293 cells were transfected in six-well plates, lysed 12±18 hr afterto Cot/Tpl-2.
transfection, and immunoprecipitated with antibodies and protein
A-agarose beads as described above. Immunoprecipitated beadsExperimental Procedures
were further washed with kinase buffer containing 10 mM Hepes
(pH 7.4), 1 mM MnCl2, 5 mM MgCl2, 12.5 mM b-glycero-2-phosphate,Expression Vectors and Biological Reagents
50 mM Na3VO4, 2 mM NaF, and 50 mM DTT. After suspension in 20The kB-luciferase reporter plasmid was obtained from Stratagene
ml of kinase buffer, the immunopreciptates were incubated with(La Jolla, CA). The LacZ reporter construct driven by the RSV LTR
5 mCi [g-32P]ATP (6000 Ci/mmol) and 1 mg of recombinant GST-(6RZ) was obtained from D. Pearce (University of California, San
IkBa(1±62) as an exogenous substrate for 30 min at 308C. The reac-Francisco, CA). The 4xRE/AP-luciferase reporters were obtained
tion was terminated by adding SDS sample buffer. The samplesfrom A. Weiss (University of California, San Francisco, CA) and have
were analyzed by SDS-PAGE, transferred to nitrocellulose mem-been described elsewhere (Shapiro et al., 1997). The human Cot
branes, and exposed to Hyperfilm MP (Amersham Life Sciences).cDNA was amplified by PCR from its original vector (generously
The membranes were subsequently probed with antibodies to deter-provided by Dr. Fumihiko Hamada, Osaka University, Japan). The
mine the levels of immunoprecipitated kinases.PCR product was cloned as a BamHI±EcoRI fragment into the pRK5
or pCDNA3 vectors, in frame with an N-terminal Myc epitope tag,
In Vivo Radiolabeling with [32P] Orthophosphoric Acidand the resulting vector was designated pRK-Myc-Cot. The kinase-
293 cells were transfected with expression plasmids encoding wild-deficient mutant of Cot-(K167M) was generated by overlapping PCR.
type and kinase-deficient versions of Cot and a kinase-deficientThe wild-type and kinase-deficient versions of NIK, IKKa, and IKKb
mutant of NIK. Twenty-four hours after transfection, the cells werehave been described elsewhere (Geleziunas et al., 1998; Lin et al.,
washed once in phosphate-free DMEM (Life Technologies) supple-1998). Recombinant human TNFa was purchased from Endogen
mented with 10% dialyzed heat-inactivated fetal bovine serum and(Cambridge, MA). Mouse anti-human CD28 monoclonal antibodies
starved for 1 hr in the same medium. [32P]-orthophosphoric acid (0.5were from Caltag (Burlingame, CA). Mouse anti-human CD3 mono-
mCi) was then added to the cells. After incubation for 2 hr, the cellsclonal antibodies (OKT3) were obtained from the UCSF pharmacy.
were lysed in ELB buffer and immunoprecipitated with anti-Myc-The human 293 cell line was maintained in DMEM supplemented
Tag antibody coupled to Protein A-agarose as described above.with 10% heat-inactivated fetal bovine serum, penicillin, and strep-
Immunoprecipitates were analyzed by SDS-PAGE, transferred totomycin. Jurkat E6±1 cells were maintained in RPMI 1640 medium
nitrocellulose membranes, and exposed to Hyperfilm MP. Immu-supplemented with serum and antibiotics as noted above. Jurkat T
noblotting was performed with anti-Myc-Tag antibodies to assesscell lines stably expressing Myc-Cot were generated by transfecting
the levels of immunoprecipitated Cot and NIK proteins.pCDNA3-Myc-Cot plasmid into Jurkat cells and selecting for the
cultures for G418 resistant cells. Several cell lines were generated
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Note Added in Proof
While this paper was under review, Tsatsanis and colleagues simi-
larly described COT/Tel-2 induction of NF-kB (Oncogene 17, 2609±
2618, 1998).
